Gene · 5552
SRGN: serglycin
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SRGN: serglycin. Genes, record 5552. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5552
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P10124 | Serglycin | 158 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents66
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 63015 | P10124 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1061 | P10124 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 12816 | P10124 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 7805 | P10124 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 7805 | P10124 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1061 | P10124 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 36489 | P10124 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 12816 | P10124 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 12816 | P10124 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 36489 | P10124 | Espacenet |
1 to 10 of 66
See all 66 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants777
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SRGN papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
| P30AI027767 | UAB Center for AIDS Research (CFAR) | 2 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 2 | 2025 |
| P30CA023168 | Cancer Center Support Grant | 2 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 2 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 2 | 2025 |
| P41GM108538 | National Center for Quantitative Biology of Complex Systems | 2 | 2025 |
| R01AR064327 | Reprogramming and Directed Differentiation of Skeletal Muscle Cells from hPSCs | 2 | 2025 |
1 to 10 of 777Source NIH's project files
See all 777 nih grantsPapers1,669
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Patients With Pancreatitis-Related Gene Variants Showed Higher Incidence of Hyperpancreatic Enzymemia After Endoscopic Retrograde Cholangiopancreatography. | DEN Open | 2027 | 42058267 | PubTator, text mining | PubMed |
| From Machine Learning-Enhanced Proteomics to a Validated Diagnostic Model: A Pipeline for Breast Cancer Biomarker Discovery via Independent and Transcriptomic Corroboration. | Bioengineering (Basel) | 2026 | 42791912 | PubTator, text mining | PubMed |
| Integrating machine learning and multi-omics analysis to identify and validate key genes associated with periodontitis. | Acta Odontol Scand | 2026 | 42615493 | PubTator, text mining | PubMed |
| A single-cell sequencing-based prognostic model reveals HLA-DRA, NPC2, and PRPF38B as immune-regulatory tumor suppressors in non-small cell lung cancer. | Front Cell Dev Biol | 2026 | 42564225 | PubTator, text mining | PubMed |
| Serglycin-ROS axis mediates synergistic lethality of PI3Kγ inhibition and Azacitidine in TP53-mutated AML. | BMC Cancer | 2026 | 42464230 | PubTator, text mining | PubMed |
| Integrative multi-omics profiling reveals coordinated immunometabolic reprogramming and host-microbiome interactions in acute pancreatitis. | Front Immunol | 2026 | 42404879 | PubTator, text mining | PubMed |
| Heparan Sulfate Proteoglycans in Immunity. | Proteoglycan Res | 2026 | 42383138 | PubTator, text mining | PubMed |
| Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation. | Front Immunol | 2026 | 42338588 | PubTator, text mining | PubMed |
| Polyamine-related 4-gene prognostic signature in hepatocellular carcinoma. | Medicine (Baltimore) | 2026 | 42332538 | PubTator, text mining | PubMed |
| Serglycin Across the Disease Spectrum: A Multifunctional Proteoglycan in Inflammation and Cancer. | Curr Issues Mol Biol | 2026 | 42193059 | PubTator, text mining | PubMed |
1 to 10 of 1,669
See all 1,669 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5552
GET https://conductscience.org/api/genes/v1/5552/patents?page=2